Skip to main content
. Author manuscript; available in PMC: 2019 Dec 14.
Published in final edited form as: ACS Infect Dis. 2019 Mar 28;5(6):974–981. doi: 10.1021/acsinfecdis.9b00039

Figure 6.

Figure 6.

Serum IgG1 (A) and IgG2a (B) anti-Dnak activities at weeks 2, 4, and 6. Data are expressed as the mean with the range. Statistical significance compared to no-adjuvant control at *P < 0.05, **P < 0.01, and ***P < 0.001.